Core Viewpoint - So-Young International Inc. is set to report its financial results for Q1 2025 on May 16, 2025, before U.S. markets open, highlighting its position as a leading aesthetic treatment platform in China [1][2]. Group 1: Financial Reporting - The financial results for the first quarter ended March 31, 2025, will be announced before U.S. markets open on May 16, 2025 [1]. - An earnings conference call is scheduled for May 16, 2025, at 7:30 AM U.S. Eastern Time, with dial-in details provided for international and local participants [2]. Group 2: Company Overview - So-Young International Inc. is recognized as the leading aesthetic treatment platform in China, connecting consumers with both online services and offline treatments [3]. - The company offers access to aesthetic treatments through its online platform and branded aesthetic centers, providing curated treatment information and facilitating online reservations [3]. - So-Young is positioned to grow along the medical aesthetic value chain due to its strong brand recognition, digital reach, affordable treatments, and efficient supply chain [3].

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in the same period last year [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [10] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later in 2025, aiming to diversify its product offerings [6] - InMode remains committed to maintaining its workforce and not cutting costs, believing this will position the company to lead when market conditions improve [5] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode completed a share repurchase program, buying back 6.95 million shares for $127 million, returning over $412 million to shareholders in the past year [7] - The company has a strong balance sheet with cash and equivalents totaling $512.9 million as of March 31, 2025 [12] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [19] Question: Guidance for Q2 and market recovery - Management expressed optimism for Q2 but noted that if results do not improve significantly, guidance may need to be lowered [30] Question: Impact of tariffs on gross margins - Management explained that current tariffs could impact gross margins by approximately 2% to 3% if they remain at 10% [56] Question: Updates on operating expenses - Management confirmed that they plan to maintain investments in sales and marketing despite macro challenges [63] Question: Pricing strategy in the current market - Management decided against raising prices due to the current market conditions, emphasizing the importance of maintaining competitiveness [70] Question: Performance in Europe compared to the U.S. - Management noted that Europe performed better in Q1 2025, attributed to management changes and pricing strategies [83]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] - The company ended the quarter with cash and cash equivalents of $512.9 million [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in Q1 2024 [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [9] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later this year, reflecting its strategy to diversify offerings [6] - InMode has committed to not reducing its workforce and aims to lead the industry during the market rebound [6] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] - Management remains optimistic about a market recovery, contingent on Q2 performance [30] Other Important Information - InMode returned over $412 million to shareholders through share repurchases over the past twelve months, representing approximately 27% of total capital [7] - The company has not yet hired a new President for the U.S. and is currently led by the acting President [66] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [20][21] Question: Guidance for Q2 and market trends - Management expects Q2 to be stronger than Q1, but if results do not improve, guidance may need to be lowered [31][40] Question: Impact of tariffs on guidance - Tariffs are expected to impact gross margins by approximately 2% to 3% if they remain at 10% [57][79] Question: Updates on operating expenses - The company plans to maintain its investment in sales and marketing despite macro challenges, which may impact profitability [65] Question: Pricing strategy in the current market - Management decided not to raise prices due to the current market conditions, despite tariff impacts [70][90] Question: Performance in Europe compared to the U.S. - Europe has shown better performance due to management changes and pricing strategies, although credit conditions are tightening [83]

Financial Data and Key Metrics Changes - In Q4 2024, total revenue was RMB 369.2 million, a decrease of 5.5% year-over-year, primarily due to a decline in revenue from So-Young Prime [23] - Net loss attributable to So-Young was RMB 607.6 million, compared to a net income of RMB 17.5 million in the same period last year [27] - Non-GAAP net loss was RMB 53.2 million, compared to a non-GAAP net income of RMB 35.7 million in Q4 2023 [27] - For the full year 2024, total revenues were RMB 1.47 billion, down 2.1% year-over-year [28] Business Line Data and Key Metrics Changes - Revenue from aesthetic treatment services surged to RMB 81.3 million, up 701.6% year-over-year, driven by the expansion of the aesthetic center business [23] - Sales of medical products and maintenance services were RMB 86.2 million, down 15.2% year-over-year, primarily due to a decrease in order volume for medical equipment [23] - Cost of aesthetic treatment services was RMB 65.2 million, up 702.3% year-over-year, reflecting the expansion of the aesthetic center business [24] Market Data and Key Metrics Changes - Total GMV for verified medical aesthetic services reached RMB 356.6 million, up 3% sequentially [17] - The total number of verified paid aesthetic treatments surpassed 81,500, with over 38,000 verified paid visits recorded [10][11] - The total number of active users exceeded 39,500, indicating strong brand appeal and market demand [11] Company Strategy and Development Direction - The company is focused on vertical integration within the aesthetic medical industry, leveraging its user base and supply chain capabilities to drive growth [7][32] - Plans to deepen presence in core cities and replicate successful aesthetic centers to expand the network further [14] - The company aims to establish a leading light medical aesthetic chain with over 1,000 locations in China, which currently has a low penetration rate of chain clinics [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategy, emphasizing the importance of establishing a robust aesthetic center network and improving financial performance [32] - The company anticipates steady improvement in financial performance as market conditions stabilize and aesthetic center businesses expand [32] - Management acknowledged that while near-term profitability may be impacted by expansion efforts, the focus remains on sustainable high-quality growth [66] Other Important Information - The company recorded a one-time goodwill impairment charge of RMB 540 million for its subsidiary, impacting the bottom line [7] - Customer satisfaction remains high at 4.98 out of 5, indicating strong service quality [10] Q&A Session Summary Question: What are the latest developments in merchant support during the industry consolidation period? - Management highlighted the importance of differentiators for specialized medical aesthetic institutions to maintain pricing power and market presence [36][37] Question: How does the company adapt its strategies for centers at different stages of development? - Management explained the implementation of differentiated operational strategies for aesthetic centers in various phases to optimize performance and enhance brand influence [44][46] Question: Can the aesthetic center business maintain growth? - Management indicated that the aesthetic center network has significant growth potential, with low market penetration of chain clinics in China [51][52] Question: What is the strategy for the upstream business? - Management discussed the integration of Miracle Laser into the upstream business, focusing on product innovation and enhancing supply chain capabilities [58][60] Question: Could management share more insights into the company's financial outlook? - Management reiterated the commitment to sustainable growth through vertical integration and maintaining a balance between growth and profitability [66]